{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T05:15:58Z","timestamp":1702012558745},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00393-023-01326-5","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T13:03:28Z","timestamp":1677675808000},"page":"220-232","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psoriasisarthritis","Psoriatic arthritis"],"prefix":"10.1007","volume":"82","author":[{"given":"Stephanie","family":"Dauth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Klippstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"K\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"issue":"6","key":"1326_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","volume":"18","author":"G Schett","year":"2022","unstructured":"Schett\u00a0G, Rahman\u00a0P, Ritchlin\u00a0C, McInnes\u00a0IB, Elewaut\u00a0D, Scher\u00a0JU (2022) Psoriatic arthritis from a\u00a0mechanistic perspective. Nat Rev Rheumatol 18(6):311\u2013325","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1326_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/acr.23836","volume":"72","author":"D Solmaz","year":"2020","unstructured":"Solmaz\u00a0D, Bakirci\u00a0S, Kimyon\u00a0G, Gunal\u00a0EK, Dogru\u00a0A, Bayindir\u00a0O et\u00a0al (2020) Impact of having family history of psoriasis or psoriatic arthritis on psoriatic disease. Arthritis Care Res 72(1):63\u201368","journal-title":"Arthritis Care Res"},{"issue":"1","key":"1326_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2340\/00015555-2171","volume":"96","author":"AS L\u00f8nnberg","year":"2016","unstructured":"L\u00f8nnberg\u00a0AS, Skov\u00a0L, Duffy\u00a0DL, Skytthe\u00a0A, Kyvik\u00a0KO, Pedersen\u00a0OB et al (2016) Genetic factors explain variation in the age at onset of psoriasis: a population-based twin study. Acta Derm Venereol 96(1):35\u201338","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1326_CR4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1136\/ard.2008.089367","volume":"68","author":"V Chandran","year":"2009","unstructured":"Chandran\u00a0V, Schentag\u00a0CT, Brockbank\u00a0JE, Pellett\u00a0FJ, Shanmugarajah\u00a0S, Toloza\u00a0SMA et\u00a0al (2009) Familial aggregation of psoriatic arthritis. Ann Rheum Dis 68(5):664\u2013667","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1326_CR5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/art.39494","volume":"68","author":"L Eder","year":"2016","unstructured":"Eder\u00a0L, Haddad\u00a0A, Rosen\u00a0CF, Lee\u00a0KA, Chandran\u00a0V, Cook\u00a0R et\u00a0al (2016) The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheumatol 68(4):915\u2013923","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1326_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/annrheumdis-2016-209334","volume":"76","author":"SM Thorarensen","year":"2017","unstructured":"Thorarensen\u00a0SM, Lu\u00a0N, Ogdie\u00a0A, Gelfand\u00a0JM, Choi\u00a0HK, Love\u00a0TJ (2017) Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. Ann Rheum Dis 76(3):521\u2013525","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1326_CR7","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin\u00a0CT, Colbert\u00a0RA, Gladman\u00a0DD (2017) Psoriatic arthritis. N\u00a0Engl J Med 376(10):957\u2013970","journal-title":"N Engl J Med"},{"issue":"1","key":"1326_CR8","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/s41467-018-04450-y","volume":"9","author":"P Hegde","year":"2018","unstructured":"Hegde\u00a0P, Weiss\u00a0E, Paradis\u00a0V, Wan\u00a0J, Mabire\u00a0M, Sukriti\u00a0S et al (2018) Mucosal-associated invariant T cells are a\u00a0profibrogenic immune cell population in the liver. Nat Commun 9(1):2146","journal-title":"Nat Commun"},{"issue":"3","key":"1326_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrcardio.2014.206","volume":"12","author":"M Prasad","year":"2015","unstructured":"Prasad\u00a0M, Hermann\u00a0J, Gabriel\u00a0SE, Weyand\u00a0CM, Mulvagh\u00a0S, Mankad\u00a0R et\u00a0al (2015) Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 12(3):168\u2013176","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"1326_CR10","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaad.2017.06.028","volume":"77","author":"A Egeberg","year":"2017","unstructured":"Egeberg\u00a0A, Skov\u00a0L, Joshi\u00a0AA, Mallbris\u00a0L, Gislason\u00a0GH, Wu\u00a0JJ et\u00a0al (2017) The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J\u00a0Am Acad Dermatol 77(4):650\u2013656.e3","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1326_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","volume":"89","author":"A Onoufriadis","year":"2011","unstructured":"Onoufriadis\u00a0A, Simpson\u00a0MA, Pink\u00a0AE, Di Meglio\u00a0P, Smith\u00a0CH, Pullabhatla\u00a0V et\u00a0al (2011) Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 89(3):432\u2013437","journal-title":"Am J Hum Genet"},{"issue":"4","key":"1326_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/art.24389","volume":"60","author":"F Ciccia","year":"2009","unstructured":"Ciccia\u00a0F, Bombardieri\u00a0M, Principato\u00a0A, Giardina\u00a0A, Tripodo\u00a0C, Porcasi\u00a0R et al (2009) Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 60(4):955\u2013965","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1326_CR13","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.4049\/jimmunol.1700596","volume":"200","author":"A Soare","year":"2018","unstructured":"Soare\u00a0A, Weber\u00a0S, Maul\u00a0L, Rauber\u00a0S, Gheorghiu\u00a0AM, Luber\u00a0M et\u00a0al (2018) Cutting edge: homeostasis of innate lymphoid cells is imbalanced in psoriatic arthritis. J\u00a0Immunol 200(4):1249\u20131254","journal-title":"J Immunol"},{"issue":"5","key":"1326_CR14","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/art.33507","volume":"64","author":"TJ Kenna","year":"2012","unstructured":"Kenna\u00a0TJ, Davidson\u00a0SI, Duan\u00a0R, Bradbury\u00a0LA, McFarlane\u00a0J, Smith\u00a0M et al (2012) Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis. Arthritis Rheum 64(5):1420\u20131429","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1326_CR15","doi-asserted-by":"publisher","first-page":"e002074","DOI":"10.1136\/rmdopen-2021-002074","volume":"8","author":"IB McInnes","year":"2022","unstructured":"McInnes\u00a0IB, Sawyer\u00a0LM, Markus\u00a0K, LeReun\u00a0C, Sabry-Grant\u00a0C, Helliwell\u00a0PS (2022) Targeted systemic therapies for psoriatic arthritis: a\u00a0systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open 8(1):e2074","journal-title":"RMD Open"},{"issue":"3","key":"1326_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","volume":"15","author":"JU Scher","year":"2019","unstructured":"Scher\u00a0JU, Ogdie\u00a0A, Merola\u00a0JF, Ritchlin\u00a0C (2019) Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol 15(3):153\u2013166","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"1326_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11926-012-0262-6","volume":"14","author":"A Haddad","year":"2012","unstructured":"Haddad\u00a0A, Chandran\u00a0V (2012) How can psoriatic arthritis be diagnosed early? Curr Rheumatol Rep 14(4):358\u2013363","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"1326_CR18","doi-asserted-by":"crossref","first-page":"157\u201360","DOI":"10.1007\/s00393-009-0462-2","volume":"69","author":"P H\u00e4rle","year":"2010","unstructured":"H\u00e4rle\u00a0P, Hartung\u00a0W, Lehmann\u00a0P, Ehrenstein\u00a0B, Schneider\u00a0N, M\u00fcller\u00a0H et\u00a0al (2010) Detection of psoriasis arthritis with the GEPARD patient questionnaire in a\u00a0dermatologic outpatient setting. Z\u00a0Rheumatol 69(2):157\u201360\u20131162\u20133","journal-title":"Z Rheumatol"},{"issue":"1","key":"1326_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40744-018-0132-4","volume":"6","author":"LJ Tucker","year":"2018","unstructured":"Tucker\u00a0LJ, Coates\u00a0LC, Helliwell\u00a0PS (2018) Assessing disease activity in psoriatic arthritis: a literature review. Rheumatol Ther 6(1):23\u201332","journal-title":"Rheumatol Ther"},{"issue":"5","key":"1326_CR20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels\u00a0MM, Aletaha\u00a0D, Alasti\u00a0F, Smolen\u00a0JS (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75(5):811\u2013818","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1326_CR21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy\u00a0PJ, Helliwell\u00a0PS (2008) Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 59(5):686\u2013691","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1326_CR22","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/ard.2007.084244","volume":"68","author":"WP Maksymowych","year":"2009","unstructured":"Maksymowych\u00a0WP, Mallon\u00a0C, Morrow\u00a0S, Shojania\u00a0K, Olszynski\u00a0WP, Wong\u00a0RL et\u00a0al (2009) Development and validation of the spondyloarthritis research consortium of Canada (SPARCC) enthesitis index. Ann Rheum Dis 68(6):948\u2013953","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1326_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10067-014-2734-8","volume":"34","author":"G K\u0131l\u0131\u00e7","year":"2015","unstructured":"K\u0131l\u0131\u00e7\u00a0G, K\u0131l\u0131\u00e7\u00a0E, Nas\u00a0K, Karkucak\u00a0M, \u00c7apk\u0131n\u00a0E, Da\u011fl\u0131\u00a0AZ et\u00a0al (2015) Comparison of ASDAS and BASDAI as a\u00a0measure of disease activity in axial psoriatic arthritis. Clin Rheumatol 34(3):515\u2013521","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1326_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson\u00a0T, Pettersson\u00a0U (1978) Severe psoriasis\u2014oral therapy with a\u00a0new retinoid. Dermatologica 157(4):238\u2013244","journal-title":"Dermatologica"},{"issue":"9","key":"1326_CR25","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.jid.2018.01.041","volume":"138","author":"JF Merola","year":"2018","unstructured":"Merola\u00a0JF, Amato\u00a0DA, See\u00a0K, Burge\u00a0R, Mallinckrodt\u00a0C, Ojeh\u00a0CK et\u00a0al (2018) Evaluation of sPGA \u00d7 BSA as an outcome measure and treatment target for clinical practice. J\u00a0Invest Dermatol 138(9):1955\u20131961","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1326_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates\u00a0LC, Fransen\u00a0J, Helliwell\u00a0PS (2010) Defining minimal disease activity in psoriatic arthritis: a\u00a0proposed objective target for treatment. Ann Rheum Dis 69(1):48\u201353","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1326_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen\u00a0JS, Sch\u00f6ls\u00a0M, Braun\u00a0J, Dougados\u00a0M, FitzGerald\u00a0O, Gladman\u00a0DD et\u00a0al (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 77(1):3\u201317","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1326_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/art.40391","volume":"70","author":"LC Coates","year":"2018","unstructured":"Coates\u00a0LC, FitzGerald\u00a0O, Merola\u00a0JF, Smolen\u00a0J, van Mens\u00a0LJJ, Bertheussen\u00a0H et al (2018) Group for research and assessment of psoriasis and psoriatic arthritis\/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol 70(3):345\u2013355","journal-title":"Arthritis Rheumatol"},{"issue":"10012","key":"1326_CR29","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates\u00a0LC, Moverley\u00a0AR, McParland\u00a0L, Brown\u00a0S, Navarro-Coy\u00a0N, O\u2019Dwyer\u00a0JL et al (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a\u00a0UK multicentre, open-label, randomised controlled trial. Lancet 386(10012):2489\u20132498","journal-title":"Lancet"},{"issue":"2","key":"1326_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/ard.2010.129379","volume":"70","author":"A Mumtaz","year":"2011","unstructured":"Mumtaz\u00a0A, Gallagher\u00a0P, Kirby\u00a0B, Waxman\u00a0R, Coates\u00a0LC, Veale\u00a0JD et\u00a0al (2011) Development of a\u00a0preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 70(2):272\u2013277","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1326_CR31","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","volume":"72","author":"PS Helliwell","year":"2013","unstructured":"Helliwell\u00a0PS, FitzGerald\u00a0O, Fransen\u00a0J, Gladman\u00a0DD, Kreuger\u00a0GG, Callis-Duffin\u00a0K et al (2013) The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 72(6):986\u2013991","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1326_CR32","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.23345","volume":"70","author":"PS Helliwell","year":"2018","unstructured":"Helliwell\u00a0PS, Kavanaugh\u00a0A (2018) Radiographic progression in psoriatic arthritis achieving a\u00a0good response to treatment: data using newer composite indices of disease activity. Arthritis Care Res (Hoboken) 70(5):797\u2013800","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"1326_CR33","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3899\/jrheum.140172","volume":"41","author":"PS Helliwell","year":"2014","unstructured":"Helliwell\u00a0PS, FitzGerald\u00a0O, Fransen\u00a0J (2014) Composite disease activity and responder indices for psoriatic arthritis: a\u00a0report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J\u00a0Rheumatol 41(6):1212\u20131217","journal-title":"J Rheumatol"},{"issue":"8","key":"1326_CR34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates\u00a0LC, Soriano\u00a0ER, Corp\u00a0N, Bertheussen\u00a0H, Callis Duffin\u00a0K, Campanholo\u00a0CB et\u00a0al (2022) Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 18(8):465\u2013479","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"1326_CR35","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec\u00a0L, Baraliakos\u00a0X, Kerschbaumer\u00a0A, de Wit\u00a0M, McInnes\u00a0I, Dougados\u00a0M et\u00a0al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700\u2013712","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1326_CR36","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/acr.20155","volume":"62","author":"LC Coates","year":"2010","unstructured":"Coates\u00a0LC, Helliwell\u00a0PS (2010) Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 62(7):965\u2013969","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"1326_CR37","doi-asserted-by":"publisher","first-page":"e001083","DOI":"10.1136\/rmdopen-2019-001083","volume":"6","author":"E Dures","year":"2020","unstructured":"Dures\u00a0E, Shepperd\u00a0S, Mukherjee\u00a0S, Robson\u00a0J, Vlaev\u00a0I, Walsh\u00a0N et al (2020) Treat-to-target in PsA: methods and necessity. RMD Open 6(1):e1083","journal-title":"RMD Open"},{"issue":"8","key":"1326_CR38","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","volume":"51","author":"GH Kingsley","year":"2012","unstructured":"Kingsley\u00a0GH, Kowalczyk\u00a0A, Taylor\u00a0H, Ibrahim\u00a0F, Packham\u00a0JC, McHugh\u00a0NJ et al (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 51(8):1368\u20131377","journal-title":"Rheumatology"},{"issue":"8","key":"1326_CR39","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/1756-185X.13599","volume":"22","author":"Q Dai","year":"2019","unstructured":"Dai\u00a0Q, Xu\u00a0L, Yu\u00a0X (2019) Efficacy and safety of leflunomide in psoriatic arthritis treatment: a single-arm meta-analysis. Int J Rheum Dis 22(8):1498\u20131505","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"1326_CR40","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1002\/art.20253","volume":"50","author":"JP Kaltwasser","year":"2004","unstructured":"Kaltwasser\u00a0JP, Nash\u00a0P, Gladman\u00a0D, Rosen\u00a0CF, Behrens\u00a0F, Jones\u00a0P et al (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a\u00a0multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50(6):1939\u20131950","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1326_CR41","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3899\/jrheum.140876","volume":"41","author":"ML Acosta Felquer","year":"2014","unstructured":"Acosta Felquer\u00a0ML, Coates\u00a0LC, Soriano\u00a0ER, Ranza\u00a0R, Espinoza\u00a0LR, Helliwell\u00a0PS et\u00a0al (2014) Drug therapies for peripheral joint disease in psoriatic arthritis: a\u00a0systematic review. J\u00a0Rheumatol 41(11):2277\u20132285","journal-title":"J Rheumatol"},{"issue":"6","key":"1326_CR42","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1586\/17512433.2016.1159130","volume":"9","author":"X Qu","year":"2016","unstructured":"Qu\u00a0X, Zhang\u00a0S, Tao\u00a0L, Song\u00a0Y (2016) A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE). Expert Rev Clin Pharmacol 9(6):799\u2013805","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"9","key":"1326_CR43","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.3899\/jrheum.151376","volume":"43","author":"M Cutolo","year":"2016","unstructured":"Cutolo\u00a0M, Myerson\u00a0GE, Fleischmann\u00a0RM, Liot\u00e9\u00a0F, D\u00edaz-Gonz\u00e1lez\u00a0F, Van den Bosch\u00a0F et al (2016) A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J\u00a0Rheumatol 43(9):1724\u20131734","journal-title":"J Rheumatol"},{"issue":"16","key":"1326_CR44","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman\u00a0D, Rigby\u00a0W, Azevedo\u00a0VF, Behrens\u00a0F, Blanco\u00a0R, Kaszuba\u00a0A et\u00a0al (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N\u00a0Engl J Med 377(16):1525\u20131536","journal-title":"N Engl J Med"},{"issue":"6","key":"1326_CR45","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s13555-021-00602-z","volume":"11","author":"K Fahrbach","year":"2021","unstructured":"Fahrbach\u00a0K, Sarri\u00a0G, Phillippo\u00a0DM, Neupane\u00a0B, Martel\u00a0SE, Kiri\u00a0S et al (2021) Short-term efficacy of biologic therapies in moderate-to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis. Dermatol Ther (Heidelb) 11(6):1965\u20131998","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1326_CR46","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","volume":"362","author":"CEM Griffiths","year":"2010","unstructured":"Griffiths\u00a0CEM, Strober\u00a0BE, van de Kerkhof\u00a0P, Ho\u00a0V, Fidelus-Gort\u00a0R, Yeilding\u00a0N et al (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N\u00a0Engl J Med 362(2):118\u2013128","journal-title":"N Engl J Med"},{"issue":"4","key":"1326_CR47","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","volume":"48","author":"EG Araujo","year":"2019","unstructured":"Araujo\u00a0EG, Englbrecht\u00a0M, Hoepken\u00a0S, Finzel\u00a0S, Kampylafka\u00a0E, Kleyer\u00a0A et\u00a0al (2019) Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum 48(4):632\u2013637","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1326_CR48","doi-asserted-by":"publisher","first-page":"rkaa070","DOI":"10.1093\/rap\/rkaa070","volume":"4","author":"K Geale","year":"2020","unstructured":"Geale\u00a0K, Lindberg\u00a0I, Paulsson\u00a0EC, Wennerstr\u00f6m\u00a0ECM, Tj\u00e4rnlund\u00a0A, Noel\u00a0W et al (2020) Persistence of biologic treatments in psoriatic arthritis: a\u00a0population-based study in Sweden. Rheumatol Adv Pract 4(2):rkaa70","journal-title":"Rheumatol Adv Pract"},{"issue":"4","key":"1326_CR49","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/art.41553","volume":"73","author":"IB McInnes","year":"2021","unstructured":"McInnes\u00a0IB, Rahman\u00a0P, Gottlieb\u00a0AB, Hsia\u00a0EC, Kollmeier\u00a0AP, Chakravarty\u00a0SD et al (2021) Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. Arthritis Rheumatol 73(4):604\u2013616","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"1326_CR50","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1111\/jdv.17931","volume":"36","author":"LE Kristensen","year":"2022","unstructured":"Kristensen\u00a0LE, Soliman\u00a0AM, Papp\u00a0K, Merola\u00a0JF, Barcomb\u00a0L, Wang\u00a0Z et\u00a0al (2022) Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1. J\u00a0Eur Acad Dermatol Venereol 36(5):e389\u201392","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1326_CR51","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/acr2.11097","volume":"2","author":"PJ Mease","year":"2020","unstructured":"Mease\u00a0PJ, Kavanaugh\u00a0A, Reimold\u00a0A, Tahir\u00a0H, Rech\u00a0J, Hall\u00a0S et al (2020) Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5\u2011year results from the phase 3 FUTURE 1 study. ACR Open Rheumatol 2(1):18\u201325","journal-title":"ACR Open Rheumatol"},{"issue":"6","key":"1326_CR52","first-page":"890","volume":"77","author":"P Mease","year":"2018","unstructured":"Mease\u00a0P, van der Heijde\u00a0D, Landew\u00e9\u00a0R, Mpofu\u00a0S, Rahman\u00a0P, Tahir\u00a0H et al (2018) Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5\u00a0study. Ann Rheum Dis 77(6):890\u2013897","journal-title":"Ann Rheum Dis"},{"issue":"9993","key":"1326_CR53","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CEM Griffiths","year":"2015","unstructured":"Griffiths\u00a0CEM, Reich\u00a0K, Lebwohl\u00a0M, van de Kerkhof\u00a0P, Paul\u00a0C, Menter\u00a0A et al (2015) Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER\u20112 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 386(9993):541\u2013551","journal-title":"Lancet"},{"issue":"1","key":"1326_CR54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease\u00a0PJ, Smolen\u00a0JS, Behrens\u00a0F, Nash\u00a0P, Leage\u00a0SL, Li\u00a0L et al (2020) A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a\u00a0randomised, open-label, blinded-assessor trial. Ann Rheum Dis 79(1):123\u2013131","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1326_CR55","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease\u00a0PJ, Gottlieb\u00a0AB, van der Heijde\u00a0D, FitzGerald\u00a0O, Johnsen\u00a0A, Nys\u00a0M et al (2017) Efficacy and safety of abatacept, a\u00a0T-cell modulator, in a\u00a0randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 76(9):1550\u20131558","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01326-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-023-01326-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01326-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T02:05:23Z","timestamp":1702001123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-023-01326-5"}},"subtitle":["Klinische Herausforderungen und medikament\u00f6ses Management","Clinical challenges and pharmaceutical management"],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1326"],"URL":"https:\/\/doi.org\/10.1007\/s00393-023-01326-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"assertion":[{"value":"16 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>S.\u00a0Dauth<\/b>: A.\u00a0Finanzielle Interessen: S.\u00a0Dauth gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Verantwortliche der Einheit Medical Writing & Wissenschaft in der Abteilung klinische Forschung beim Fraunhofer-Institut f\u00fcr Translationale Medizin und Pharmakologie (ITMP); Leitung der Gesch\u00e4ftsstelle des Fraunhofer Cluster of Excellence Immune-Mediated Diseases (CIMD). <b>M.\u00a0Klippstein<\/b>: A.\u00a0Finanzielle Interessen: M.\u00a0Klippstein gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: angestellter klinischer Pharmakologie am Fraunhofer ITMP Frankfurt. <b>M.\u00a0K\u00f6hm<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: GSK, Pfizer.\u00a0\u2013 Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: AbbVie, Pfizer, Janssen, BMS, GSK, Novartis, Amgen, Celgene.\u00a0\u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00c4.: AbbVie, Pfizer, Janssen, BMS, GSK, Novartis, Amgen, Celgene.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Ober\u00e4rztin, Abteilung Rheumatologie, Universit\u00e4tsklinikum Frankfurt; Stellvertretende Abteilungsleitung Klinische Forschung, Fraunhofer Institut f\u00fcr Translationale Medizin & Pharmakologie (ITMP) | Mitgliedschaft DGRh, DGIM.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung aufExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}